PAVM vs. TTOO, MHUA, SSKN, GCTK, PETV, PYPD, MBOT, NXGL, IINN, and NEPH
Should you be buying PAVmed stock or one of its competitors? The main competitors of PAVmed include T2 Biosystems (TTOO), Meihua International Medical Technologies (MHUA), STRATA Skin Sciences (SSKN), GlucoTrack (GCTK), PetVivo (PETV), PolyPid (PYPD), Microbot Medical (MBOT), NEXGEL (NXGL), Inspira Technologies Oxy B.H.N. (IINN), and Nephros (NEPH). These companies are all part of the "surgical & medical instruments" industry.
T2 Biosystems (NASDAQ:TTOO) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.
23.2% of T2 Biosystems shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 0.1% of T2 Biosystems shares are owned by insiders. Comparatively, 12.6% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
T2 Biosystems presently has a consensus price target of $3.00, indicating a potential downside of 7.98%. PAVmed has a consensus price target of $21.00, indicating a potential upside of 881.31%. Given T2 Biosystems' higher probable upside, analysts plainly believe PAVmed is more favorable than T2 Biosystems.
T2 Biosystems has higher revenue and earnings than PAVmed.
T2 Biosystems has a net margin of -696.19% compared to T2 Biosystems' net margin of -2,617.25%.
T2 Biosystems received 206 more outperform votes than PAVmed when rated by MarketBeat users. However, 65.79% of users gave PAVmed an outperform vote while only 64.65% of users gave T2 Biosystems an outperform vote.
T2 Biosystems has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.
In the previous week, PAVmed had 2 more articles in the media than T2 Biosystems. MarketBeat recorded 4 mentions for PAVmed and 2 mentions for T2 Biosystems. T2 Biosystems' average media sentiment score of 0.33 beat PAVmed's score of -0.50 indicating that PAVmed is being referred to more favorably in the news media.
Summary
PAVmed beats T2 Biosystems on 8 of the 13 factors compared between the two stocks.
Get PAVmed News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
